RNS Number : 4316Z MaxCyte, Inc. 07 August 2024 MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2024 ROCKVILLE, MD , August 7, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
RNS Number : 4498Z MaxCyte, Inc. 07 August 2024 MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD , August 7, 2024 — MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and innovative
RNS Number : 8744Y MaxCyte, Inc. 01 August 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, MD , August 1, 2024 : MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
RNS Number : 4698Y MaxCyte, Inc. 31 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , July 31, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
RNS Number : 8525V MaxCyte, Inc. 10 July 2024 MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024 ROCKVILLE, MD , July 10, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT ), a leading, cell-engineering focused company providing enabling platform technologies to advance the
ROCKVILLE, Md., July 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 6718V MaxCyte, Inc. 09 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Change of Name of Nominated Adviser and Broker ROCKVILLE, MD , July 9, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8834U MaxCyte, Inc. 03 July 2024 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting
RNS Number : 8115U MaxCyte, Inc. 02 July 2024 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options and PDMR dealing ROCKVILLE, MD , July 2, 2024 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
